Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Research Partnership publishes 2017 Living with NASH report

Research Partnership
Posted on: 25 Aug 17
 Research Partnership publishes 2017 Living with NASH report

Healthcare market research and consultancy specialist Research Partnership has published a new Living with Non-alcoholic Steatohepatitis (NASH / NAFLD) report for 2017.

Living with Non-alcoholic Steatohepatitis (NASH) is a quantitative US study conducted online amongst patients. The report consists of 45-minute online interviews with 108 NASH / NAFLD patients; a small number of qualitative interviews were also conducted.

NASH is a type of non-alcoholic fatty liver disease in which inflammation and liver cell damage exists in addition to fat in the liver. It can lead to complications, such as cirrhosis and liver cancer. Prevalence of NASH (which is estimated to be 6% in the US) is linked to obesity and Type 2 diabetes and as these two conditions increase in prevalence, NASH is also expected to become more common.

Head of Living with, Mariel Metcalfe commented, “This study addresses the need for patient understanding of those living with NASH / NAFLD from pre-diagnosis to current management. This report provides comprehensive, quantitative insights into patient behaviours and also identifies their feelings and perceptions at key stages of their journey.”

Currently being conducted in the US but looking to expand the survey to the EU, Living with NASH is just one in a series of reports offering comprehensive insight into the chronic disease patient journey from pre-diagnosis to stabilisation. Living with Lupus (SLE) (EU & US), Crohn’s (EU & US), Chronic Pain (US), Rheumatoid Arthritis (EU & US), PsA (EU) and Ulcerative Colitis (EU) reports have recently been published and are available to purchase. Other therapy areas will be launched later in the year, including Ankylosing Spondylitis, Atopic Dermatitis, Multiple Sclerosis and Psoriasis amongst others.

More detailed findings from the study can be provided from Mariel Metcalfe on

For more information:

Editor's Details

Owen Bennett
Research Partnership
+44 7584 625 836

Last updated on: 25/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.